Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Pfizer has been awarded ... around the same time as GSK is expecting a readout from its AResVI trial in this age bracket. Following after are RSV vaccines from Johnson & Johnson as well as Moderna ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Sales of GSK (NYSE:GSK) and Pfizer’s (NYSE:PFE) RSV vaccines have reportedly fallen since U.S. regulators narrowed the ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

China is yet to approve a RSV vaccine, unlike the U.S. which has given the green light to shots from GSK, Moderna and Pfizer, but multiple candidates have reached the clinic ahead of Ab&B.

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...